Publication | Closed Access

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen–related apple allergy

Apple AllergyAllergySublingual ImmunotherapyAllergy MedicineImmunologyPeanut AllergyOral ImmunotherapyAllergenFood AllergiesImmunotherapyMedicine